Seanna Grob, MD
Ophthalmic Plastic and Reconstructive Surgery · Orange, CANPI 1013262104
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $551 of the $616 with a category attached, or 89.5%. 7 manufacturers reported payments, led by Amgen at 40.4% of the total. 2025 is the largest year on record at $303, 4.7 times the $65 reported in 2020. That places this record below the midpoint for ophthalmic plastic and reconstructive surgery clinicians in CA, where the typical reported total is $1,399.
Across 11 payments — averaging $55.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$248
- Bausch & Lomb Americas Inc.$139
- Dompe US, Inc.$119
- Merz Pharmaceuticals, LLC$34
- Astellas Pharma US Inc$34
- Alcon$24
- plus $15 from 1 others
What the payments were for
- Consulting fees$6511%
- Food & beverage$55189%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 5 | $248 |
| Bausch & Lomb Americas Inc. | 1 | $139 |
| Dompe US, Inc. | 1 | $119 |
| Merz Pharmaceuticals, LLC | 1 | $34 |
| Astellas Pharma US Inc | 1 | $34 |
| Alcon | 1 | $24 |
| Novus Surgical Consultants | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$616 in reported general payments places this provider in the 25th percentile of 50 ophthalmic plastic and reconstructive surgery providers in California.
See all ophthalmic plastic and reconstructive surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 87 | $748 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 49 | $473 |
| Latanoprost | 11 | $52 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in Orange
- Marjan FaridIrvine$742K
- Jeffrey JosephNewport Beach$292K
- Sandy Zhang-NunesLos Angeles$149K
- Soheab UgradarLos Angeles$131K
- Andrea KosslerStanford$91K
- Nicolas BiroWest Covina$76K
- Joseph ChangBakersfield$74K
- Anupam JayaramMenlo Park$26K
- Charles KimStockton$21K
- Omar OzgurMission Viejo$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.